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 80 
 81 
The rapid increase in prevalence and health costs associated with type 2 diabetes has been 82 
observed worldwide [1]. It has been estimated that the risk of hospitalisation is two-fold higher in 83 
people with diabetes compared to those without diabetes, and the proportion with diabetes 84 
is >10% in those admitted to hospital at any one time [2]. Among some specific age-strata, the 85 
proportion is over 20% [3]. The associated costs of excess admissions, as well as increased costs 86 
per admission, are significant contributors to the financial burden borne by healthcare systems 87 
from diabetes and often reflect preventable morbidity suffered by patients [4].  Systolic blood 88 
pressure (SBP), as the most common modifiable risk factor, has been found to be associated 89 
both with cardiovascular diseases (CVD) mortality and CVD hospitalisation among people with 90 
type 2 diabetes [5,6]. However, no established association between SBP and inpatient cost due 91 
to CVD hospitalisation has been shown among people with type 2 diabetes. Although a target 92 
SBP has been agreed to lower the risk of e.g. CVD mortality and CVD hospitalisation, it is unclear 93 
whether this threshold will impact on inpatient costs due to CVD mortality. 94 
Diabetes peer support involves people with diabetes assisting each other to improve their social, 95 
mental and physical wellbeing.  Peer support can be provided through individual or group 96 
approaches and either face-to-face, telephone or online contact.   It is generally seen as a low 97 
cost intervention, and has been suggested to reduce health-care costs [7].   Some studies have 98 
reported that peer support can reduce health-care costs among people with type 2 diabetes 99 
[8,9].  The RAndomised controlled trial of Peer Support In type 2 Diabetes (RAPSID) was the 100 
largest randomised controlled trial (RCT) of type 2 diabetes peer support to date [10].  The 101 
intervention was recently shown to be cost-effective during the trial based on self-reported costs 102 
[11] and also from prospective hospital costs. In RAPSID, group peer support was associated with 103 
2-3 mm Hg lower SBP, however, it was unclear whether this was a mediator in the reduction in 104 
inpatient costs, and whether this was through an effect on CVD hospitalisation specifically. 105 
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In this study, we aimed to investigate the association between SBP measured in primary care 106 
settings and inpatient cost for CVD hospitalisation over the next 2 years accounting for the risk of 107 
hospitalisation among people with type 2 diabetes, using data from two cohorts. We then 108 
examine the impact of peer support on this association. 109 
MATERIALS AND METHODS 110 
 111 
We followed the methods of Dahai Yu et al. 2018 for the data and data collection [12]. Briefly we 112 
utilised two cohorts from Cambridgeshire, England: one (main cohort) based on the electronic 113 
health record data from primary care settings to develop our CVD hospitalisation and re-114 
hospitalisation risk scores and another (replication cohort) based on post-trial cohort data for 115 
external validation.  116 
 117 
Patient lists from 18 general practices across Cambridgeshire, England, in 2008/2009 were 118 
collated and linked with hospital admissions (Secondary Uses Service) data as part of an 119 
evaluation of diabetes care across the county by the local health board, National Health Service 120 
(NHS) Cambridgeshire. This cohort was limited to volunteer practices using the Egton Medical 121 
Information Systems general practitioner software system, from which a predefined set of data 122 
could be extracted. There was no systematic selection process for these surgeries, and data 123 
extracted were for their entire diabetes population. All patients with diabetes had follow-up 124 
hospitalisation data to 2010Ȃ2011. Hospital admissions to NHS and private hospitals within and 125 
outside Cambridgeshire were followed-up. No personal identifiers were released to researchers, 126 
and all subsequent analyses were conducted on anonymised datasets.  127 
 128 
The design and methods of the RAPSID trial have been published previously [10], as have its 129 
Consolidated Standards of Reporting Trials diagram and the results of its primary outcomes [10].  130 
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Briefly, RAPSID was a 2x2 factorial cluster RCT comparing 4 groups: Controls, 1:1 (individual) peer 131 
support, group peer support, and combined 1:1 and group peer support among patients with type 132 
2 diabetes. Participants had their diabetes for at least 12 months and those with dementia or 133 
psychotic illness were excluded. Participants were recruited from communities across 134 
Cambridgeshire and neighbouring areas of Essex and Hertfordshire.  Follow up data were only 135 
available for participants in Cambridgeshire and neighbouring areas of Hertfordshire that are 136 
served by the Cambridgeshire and Peterborough Clinical Commissioning Group (CCG). Clusters 137 
ȋǮǯȌǤ138 
following a pilot, using a framework defined by Peers for Progress [11].  Peers facilitating peer 139 
support were termed peer support facilitators and their selection, training, support and the 140 
overall programme are described elsewhere [10].  The intervention lasted 8-12 months and was 141 
commenced and concluded, cluster by cluster, between 02/06/11 to 12/04/12.  Ethics approval was 142 
received from the Cambridgeshire REC2 Committee (10/H0308/72), and signed consent included 143 
agreement for access to hospital data.   144 
Demographic data, blood pressure, and HbA1c and lipid profiles information were collected at 145 
baseline. Blood pressure were measured using the Omron 705IT Electronic BP Monitor [13]. Each 146 
participant was followed up until June 2015 (0.91-4.07 yearsǯ-up from beginning/entry into 147 
the trial).  Hospitalisation (NHS hospitals & private hospitals), Accident & Emergency and 148 
outpatient visits within/outside Cambridgeshire and the included areas of Hertfordshire were 149 
collected through Cambridgeshire and Peterborough Clinical CCG [14] as well as elective/non-150 
elective status, and International Classification of Diseases (ICD-10) codes[15].  151 
 152 
Ethics approval was received from the Cambridgeshire REC2 Committee (10/H0308/72), and 153 
signed consent included agreement for access to hospital data.   154 
 155 
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The primary outcome of the study was having at least one hospitalisation with CVD as the 156 
primary diagnosis (ICD-10: I20ȂI25, I60ȂI69 and I73 in the first ICD field) over the 2-year follow-up.  157 
 158 
Statistical Analysis 159 
A large proportion of the population do not attend hospital as an inpatient or outpatient in any 160 
given year and therefore health care payment data demonstrate a skewed utilisation/payment 161 
pattern [16]. To take into account the problem of Ǯzero massǯ and skewed outcomes, the demand 162 
functions were modelled using a two-part model [17]. In this two-part model, a probit model was 163 
ǲǳǤ164 
medical expenditure is defined as any healthcare expenditure greater than zero. A generalized 165 
linear model (GLM) was estimated, conditional on having healthcare expenditure. GLM was used, 166 
instead of log ordinary least squares regression, since it relaxes the normality and 167 
homoscedasticity assumption, and avoids bias associated with re-transforming to the raw scale 168 
[18]. The results of the modified Park test verified that the use of a gamma distribution, with a log 169 
link, was the best fitted GLM for consistent estimation of coefficients [19]. The variance inflation 170 
factor (VIF) for all predictors used in the two-part model indicated no-existence of multi-171 
collinearity [20]. The F-test for the two-part regression models was found to be significant, which 172 
indicated the overall significance of the regression model. Predicted inpatient cost was estimated 173 
in the two-part model by the level of baseline SBP with adjustment of other co-variables. 174 
Confidence intervals (95% CI) for estimated payments were estimated by a bootstrap process 175 
with 1000 samples.  Restricted analyses in each financial year were carried out as sensitivity 176 
analyses. All analyses were performed with STATA (STATA/SE 14.0 StataCorp Texas). 177 
 178 
 179 
 180 
 181 
In our main cohort, we analysed information on 4,704 type 2 diabetes patients with 588 CVD 182 
hospitalisations within 2 years. Our replication cohort had information on 1,121 type 2 diabetes 183 
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patients with 183 CVD hospitalisations. Table-1 summarises the basic characteristics and clinical 184 
measurements of the study population. Patients with type 2 diabetes in both cohorts had similar 185 
age, gender, blood pressure and total cholesterol. Patients in the main cohort had a higher level 186 
of high density lipoprotein, low density lipoprotein, and HbA1c. Compared with the main cohort, 187 
those in the replication cohort were more likely to be prescribed lowering lipid medicine. Baseline 188 
data for the 4 groups of the replication cohort were well matched (Table-1).   189 
As shown in Table 2, inpatient cost data from CVD hospitalisation were typically skewed due to 190 
Ǯǯ191 
expenditure. 87.5% and 83.7% of participants in the main and replication cohort were not 192 
hospitalised due to CVD diseases over the two year of follow-up. Within the replication cohort, 193 
79.7% of controls and 82.8%, 85.4% and 86.8% of patients in the 1:1 group, and combined 194 
intervention groups respectively were not hospitalised due to CVD disease. Among patients 195 
hospitalised due to CVD diseases, median inpatient costs were £4348.35 (IQR: 1623.50 to 8766.75) 196 
and £2430.72 (IQR: 793.06 to 4026.20) for the main and replication cohort, respectively. With the 197 
replication cohort, median inpatient costs were £2419.60 (1006.91 to 4387.66), £2489.40 (770.69 198 
to 4387.66), £1963.56 (714.93 to 4032.55) and £2436.00 (885.19 to 3473.12) for control, 1:1, group 199 
and combined intervention groups, respectively. 200 
Results from two-part model 201 
Dose-response relationship curves between SBP and predicted inpatient cost for CVD 202 
hospitalisation derived from the two-part models after accounting for the risk of CVD 203 
hospitalisation with adjustment of co-variables in Table-1 are presented in Figure-1 for the main 204 
cohort and the replication cohort. SBP was non-linearly associated with adjusted predicted 205 
inpatient cost for CVD hospitalisation (linearity test: all P < 0.00001) both in the main and 206 
replication cohort. The threshold was estimated at 137 (133-141) mmHg for SBP both in the main 207 
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sample and replication sample, with consistent stable adjusted predicted inpatient cost for CVD 208 
hospitalisation below the threshold and increased predicted inpatient cost above the threshold.  209 
 Within the replication cohort, dose-response relationship curves between SBP and adjusted 210 
predicted inpatient cost for CVD hospitalisation in each group is presented in Figure-2. A non-211 
linear association between SBP and adjusted predicted inpatient cost was found in control, 1:1 212 
and group intervention groups (linearity test: all P < 0.00001). The threshold at 137 (133-141) 213 
mmHg for SBP was consistently found in each group, with consistent stable adjusted predicted 214 
inpatient cost for CVD hospitalisation below the threshold and increased predicted inpatient cost 215 
above the threshold. In the combined intervention group, the adjusted predicted inpatient cost 216 
was linearly stable as SBP increased (linearity test: P=0.05263). 217 
 218 
 219 
 220 
In this study, using two prospective cohorts, we found a non-linear association between SBP 221 
measured in UK populations with type 2 diabetes and the adjusted predicted inpatient cost for 222 
CVD hospitalization over 2 years of follow-up, after accounting for the risk of CVD hospitalisation 223 
both in the main and replication cohort. Further investigation revealed: SBP below 137 mmHg was 224 
associated with stable lowest inpatient cost; inpatient cost increased with an increase in SBP 225 
above 137 mmHg. The peer support intervention, especially group intervention combined with 1:1 226 
support had a significant impact on the association between inpatient cost for CVD 227 
hospitalisation and SBP. 228 
 229 
 230 
It is well established that SBP is the major determinant of CVD risk in the population who are 231 
aged over 50 [21]. In patients with type 2 diabetes, previous studies have revealed a J-shape 232 
relationship between SBP and CVD event risk, for example, the United Kingdom Prospective 233 
Diabetes Study [22] showed a lowered CVD event rate with an attained lower BP goal of 144/82 234 
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mm Hg.  The International Verapamil SRȄTrandolapril [23] and the Avoiding CVD Events in 235 
Combination Therapy in Patients Living with Systolic Hypertension [24] trials also failed to 236 
demonstrate a CVD outcome benefit at a blood pressure below 130/80 mm Hg. We have 237 
previously shown that an SBP between 133-141 mmHg was associated with the lowest risk of CVD 238 
hospitalisation among patients with type 2 diabetes [6]. However, it was not clear whether this J-239 
shape relationship exists between SBP and inpatient costs for CVD hospitalisation as most studies 240 
analysed health cost/payments which had a skewed distribution. Ours is the first study among 241 
patients with T2DM, following adjustment for the individual probability of being hospitalised, and 242 
we now show that there is a `hockey-ǯ CVD inpatient 243 
payment.  This finding suggests that CVD inpatient payments are stable for SBP below 133-141 244 
mmHg and linearly increase above this range.  This in turn supports a SBP target between 133-141 245 
mmHg to minimise future risks of CVD hospitalisation and associated inpatient payments. 246 
Although we have shown that CVD hospital payments increase with a baseline SBP above 133-144 247 
mm Hg, this was not found to occur in the 2-year post-trial period of RAPSID intervention 248 
participants.  In RAPSID, group peer support was associated with a significant reduction in SBP 249 
after 8-12 month follow-up from baseline and we speculate that it was this lower SBP that was 250 
responsible for this finding.  Hospitalisation was shown to be reduced in Hong Kong with peer 251 
support among those who had high diabetes distress [25].  We have not been able to elucidate 252 
the mechanism behind the lower SBP in RAPSID, and have excluded a greater effect among those 253 
with high diabetes distress and medication adherence.  There was also no evidence of changes in 254 
lifestyle as measured by questionnaires, or crudely by body weight (a small reduction in waist 255 
circumference was found in the per protocol analyses).   The current finding of reduced CVD 256 
hospitalisation costs does provide some validity that the lower SBP described was not simply due 257 
to chance. 258 
 259 
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This suggests that the peer support intervention was associated with a reduced inpatient 260 
payment, however in the 2-year post-trial follow-up, among patients in the combined 261 
intervention group, CVD inpatient payment did not increase along with SBP, especially beyond 262 
133-141 mmHg, the slightly reduction in the CVD inpatient payment, suggesting that patients 263 
whose SBP beyond 133-141 mmHg were less likely to trigger the CVD hospitalisation that primarily 264 
due to the combined peer-support intervention. The potential mechanism could be that patients 265 
in the combined intervention might stick to the healthy lifestyle in the post-trial follow-up, which 266 
might have an impact ǯand SBP as observed in the trial follow-up. 267 
However, there was no post-trial measurements on obesity to prove this hypothesis. Although in 268 
the trial follow-up the SBP reduction could not be explained by the increased medication 269 
adherence as this as previously found to be unchanged [26,27], it was unclear whether anti-270 
hypertensive treatments adherence pattern was modified in the post-trial follow-up restricted by 271 
the post-trial information on the medication adherence.  272 
 273 
 274 
Strengths of the analysis include that the association between SBP and CVD inpatient payment 275 
was examined in two independent cohorts. A further strength is the minimal information bias, 276 
with the outcome used, recorded inpatient payments, having been fully recorded by the CCG 277 
[28]. In particular, as these are payment details, both NHS hospitals and private hospital 278 
admissions were able to be included.   There would have been some loss for patients where no 279 
component of care was paid for by the CCG.   280 
Some limitations have to be considered in the interpretation of our findings.  Unlike 281 
pharmaceutical interventions, where adherence can be assessed using pill counters, it is difficult 282 
to evaluate the magnitude of peer-support intervention on an individual level, and although we 283 
did record attendance and telephone calls, we did not assess engagement.  The payment/savings 284 
from similar peer-support interventions should be further investigated in other post-trial 285 
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observation studies.   A further limitation of our study is that we have not been able to describe 286 
the activities of participants after the trial was completed.  All participants were sent the results, 287 
and we are aware that some intervention (e.g. peer support groups) continued including with 288 
ǲ ?ǳ[11].  289 
 290 
Conclusion 291 
As far as we are aware, our study is the first study to examine the prospective association 292 
between SBP and 2-year estimated CVD inpatient payment. A `hockey-ǯ293 
SBP and 2-year estimated CVD inpatient payment was identified in two independent cohorts, 294 
with a consistent threshold at 133-141 mmHg and a linearly increased payment beyond the 295 
threshold. Alteration in this relationship following a combined peer-support intervention (group 296 
and 1:1 interventions) is suggested by their lack of an increase in estimated CVD payment. Our 297 
findings suggest that among people with type 2 diabetes, blood pressure management should 298 
target a SBP of 133-141 mmHg.  Integration of this threshold into clinical practice guidance, could 299 
lower both individual risk of, and associated payments for, CVD hospitalisation.  300 
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 451 
Table-1. Baseline Characteristics of study cohorts 452 
  
Main cohort 
 
Replication cohort 
All Control 1:1 Group Combined 
N 
4,702 1,121 
291 261 288 281 
Cardiovascular diseases 
hospitalisation, n (%) 
588 (12.5) 183 (16.3) 59 (20.3) 45 (17.2) 42 (14.6) 37 (13.2) 
Age, years 65.0±16.3 65.5±11.4 65.9±12.8 65.3±9.8 65.8±11.9 65.0±10.4 
Female, n (%) 1,919 (40.8) 444 (39.6) 122 (41.9) 109 (41.8) 101 (35.1) 112 (39.9) 
Systolic blood pressure, mmHg 134.5±16.0 139.7±20.2 140.0±20.6 140.4±20.6 140.8±19.5 137.9±20.3 
Diastolic blood pressure, mmHg 76.3±10.0 75.5±11.5 75.0±11.6 75.8±10.9 75.1±11.3 75.6±11.9 
Total cholesterol, mmol/L 4.3±1.2 4.2±1.7 4.3±1.5 4.3±1.3 4.1±2.0 4.3±1.7 
High density lipoprotein, mmol/L 1.3±0.6 1.1±1.2 1.2±0.9 1.2±1.0 1.0±1.5 1.1±1.1 
Low density lipoprotein, mmol/L 2.5±1.4 1.4±3.0 1.3±3.2 1.5±2.8 1.5±2.8 1.5±3.0 
Body mass index, kg/m2 30.8±6.9 32.2±6.0 32.3±6.0 32.6±6.5 32.0±5.9 32.2±5.9 
HbA1c, mmol/mol 61.5±17.2 56.2±15.1 55.6±16.2 56.5±15.0 57.3±14.7 55.3±13.8 
Lipid Lowering treatment, n (%) 3,342 (71.4) 731 (65.2) 180 (61.9) 173 (66.3) 191 (66.3) 187 (66.6) 
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 462 
 
Median cost (interquartile of cost), £  
among people with non-zero payment 
People with zero payment 
N (%) 
Main Cohort 4348.35 (1623.50 to 8766.75) 4116 (87.5) 
Replication cohort, overall 2430.72 (793.06 to 4026.20) 938 (83.7) 
Replication cohort, control 2419.60 (1006.91 to 4387.66) 232 (79.7) 
Replication cohort, group  2489.40 (770.69 to 4387.66) 216 (82.8) 
Replication cohort, 1:1 1963.56 (714.93 to 4032.55) 246 (85.4) 
Replication cohort, combined 2436.00 (885.19 to 3473.12) 244 (86.8) 
463 
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Figure-1. Adjusted association between baseline systolic blood pressure and predicted inpatient cost due to cardiovascular diseases hospitalisation in 464 
main cohort and replication cohort 465 
 466 
 467 
 468 
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Figure-2. Adjusted association between baseline systolic blood pressure and predicted inpatient cost due to cardiovascular diseases hospitalisation in 469 
groups of replication cohort 470 
 471 
 472 
 473 
 474 
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